Latest AMD Stories
TARRYTOWN, N.Y., Oct. 18, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed one-year results from the VIEW 1 and VIEW 2 Phase 3 studies of EYLEA (aflibercept) Injection were published online in the journal Ophthalmology ahead of a future print publication. The publication can be accessed at http://digitalreprints.elsevier.com/t/28599. "The article published today provides additional details about the VIEW 1 and VIEW 2 studies that...
Lawrence LeBlond for redOrbit.com - Your Universe Online Age-related Macular Degeneration (AMD) is a condition that generally occurs in people over the age of 50, but also occurs in higher numbers of people who smoke, who are white, and people who have a family history of the often debilitating condition. And for those who had gone through AMD testing, they had generally had to sit in a darkened room for 20 minutes before testing had begun. But now, researchers from Australia’s Vision...
AUSTIN, Texas, Oct. 4, 2012 /PRNewswire/ -- CanWe Studios LLC and AMD (NYSE: AMD) today announced they will work together in a unique way to transform how influencers and consumers connect during Austin City Limits. CanWeNetwork, a geospatial business networking app, will provide AMD with valuable business intelligence and a new mobile social channel through a large-scale social media marketing and branding campaign targeting the tech start-up and music scene. "The...
TARRYTOWN, N.Y., Sept. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that EYLEA(®) (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular degeneration (wet AMD) from the Japanese Ministry of Health, Labour and Welfare (MHLW). In Japan, EYLEA treatment is initiated with one 2 milligram (mg) intravitreal injection per month for three consecutive months (treatment initiation)....
AUSTIN, Texas, Sept. 25, 2012 /PRNewswire/ -- Fantastic Fest is thrilled to announce this year's Fantastic Fest Award winners. It's a terrible task to pick favorites and single out any of the magnificent films that played at this year's festival, but our esteemed team of jurors have done the nearly impossible and chosen the best and most striking films of the festival. (Logo: http://photos.prnewswire.com/prnh/20120629/DA33206LOGO) The audience awards are presented by accounting...
NEW YORK, Sept. 24, 2012 /PRNewswire/ -- In 1992, Henry Grunwald was attempting to pour himself a glass of water when he suddenly missed the glass. He first assumed he needed new glasses, before discovering he was beginning the dark voyage into the world of Macular Degeneration. Now, 13 years later after its first release, Grunwald's memoir, "Twilight; Losing Sight, Gaining Insight," is being re-released by Random House, with the help of Lighthouse International, as an e-book (in...
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). The decision of the European Commission on approval is expected in the fourth quarter of 2012. "We are pleased with the positive...
Grant from AMD Foundation Provides Ongoing Support to 10 Boys & Girls Clubs, Plus New Support for Five More ATLANTA, Aug. 9, 2012 /PRNewswire-USNewswire/ -- For the third year in a row, Boys & Girls Clubs of America (BGCA) have partnered nationally with AMD and the AMD Foundation to support technology for Club members. This year's support, in the amount of $261,000, includes several initiatives: Boys & Girls Club Day at AMD - AMD is hosting 13 Club youth ages 11-13 at...
OXFORD, England, August 8, 2012 /PRNewswire/ -- -- Treatment of final RetinoStat(R)patient cohort underway -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, and its partner Sanofi (EURONEXT: SAN and NYSE: SNY) today announce a positive interim review of the RetinoStat(R) Phase I study in neovascular "wet" age-related macular degeneration (AMD) and the StarGen(TM) Phase I/IIa study in Stargardt...
MIAMI LAKES, Fla., Aug. 6, 2012 /PRNewswire/ -- Fuse Science Inc. (OTCQB: DROP), (www.fusescience.com), today announced that it has entered into a licensing letter of intent ("LOI") with Macular Health, LLC, (www.macularhealth.com), one of the leading manufacturers of macular degeneration nutritional supplements. This is the first licensing agreement for Fuse Science in the health and nutrition field and accelerates the application of its unique delivery technology into a new...
